Title:
COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA
Document Type and Number:
WIPO Patent Application WO/2012/074842
Kind Code:
A3
Abstract:
The invention features compositions comprising agent that inhibits thymic stromal lymphopoietin (TSLP) or TSLP Receptor expression or biological activity, and related methods of using the compositions for treating or preventing cancer progression or metastasis.
Inventors:
BIRAGYN ARYA (US)
LEONARD WARREN J (US)
LEONARD WARREN J (US)
Application Number:
PCT/US2011/061872
Publication Date:
April 04, 2013
Filing Date:
November 22, 2011
Export Citation:
Assignee:
US OF AMERICA AS REPRESENTED BY THE SECRETARY NAT INST OF HEALTH (US)
BIRAGYN ARYA (US)
LEONARD WARREN J (US)
BIRAGYN ARYA (US)
LEONARD WARREN J (US)
International Classes:
A61K39/395; A61K48/00; A61P35/00
Domestic Patent References:
| WO2010086445A1 | 2010-08-05 |
Other References:
VALERIE I. BROWN ET AL.: "Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7R a signaling", CANCER RESEARCH, vol. 67, no. 20, 2007, pages 9963 - 9970
ALEXANDER PEDROZA-GONZALEZ ET AL.: "Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation", J. EXP. MED., vol. 208, no. 3, 21 February 2011 (2011-02-21), pages 479 - 490
PUREVDORJ B. OLKHANUD ET AL.: "Thymic stromal lymphopoietin is a key mediator of breast cancer progression", THE JOURNAL OF IMMUNOLOGY, vol. 186, no. 10, 13 April 2011 (2011-04-13), pages 5656 - 5662
ALEXANDER PEDROZA-GONZALEZ ET AL.: "Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation", J. EXP. MED., vol. 208, no. 3, 21 February 2011 (2011-02-21), pages 479 - 490
PUREVDORJ B. OLKHANUD ET AL.: "Thymic stromal lymphopoietin is a key mediator of breast cancer progression", THE JOURNAL OF IMMUNOLOGY, vol. 186, no. 10, 13 April 2011 (2011-04-13), pages 5656 - 5662
Attorney, Agent or Firm:
CORLESS, Peter F et al. (P.O. Box 55874Boston, MA, US)
Download PDF: